A shadow market for unapproved weight-loss medications is being driven by TikTok fitness influencers and vendors on messaging platforms, based on new investigations.
Investigational Drug Gaining Traction Online
The experimental drug, which is still in clinical trials, is being promoted by online personalities for its supposed weight-reducing properties. Followers are encouraged to message these accounts directly for source information, while also receiving promotional offers.
Thriving Trade on Messaging Platforms
Separately, a robust trade exists on messaging services, where communities with numerous of members share comparison images, administration instructions and assertions of rapid British shipping. Vendors promote the substance there before redirecting customers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, GIP and glucagon. Early trials indicate it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.
Medical Professionals Voice Worries
However, doctors and chemists have warned that the distribution of what is still an unlicensed medication in the UK is a cause for concern and could result in individuals administering substances of unknown origin.
Some professionals said the demand for retatrutide could be linked to the increasing cost of licensed slimming products such as Mounjaro.
Regulatory Position and Implementation
Selling retatrutide on TikTok or Telegram is prohibited in the UK, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.
Several content creators try to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate pharmaceutical, advertising, and consumer laws, potentially leading to fines, prosecution or imprisonment.
Platform Response and Content Elimination
Based on the social media company, the platform has taken down problematic material and prohibited related hashtags and query recommendations. The company stated it was committed to keeping the service secure and allocating resources in strengthening compliance measures.
Online Trading Activities
Investigations also discovered groups with up to nine thousand members selling the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays groups with thousands of users, filled with photos of slimming results, glowing testimonials and detailed guides for preparing or injecting at residence.
After moments of joining one group, a seller shared WhatsApp details, where most purchases take place. The vendor provided an instruction manual and promised delivery within 48 hours. When questioned whether the product was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one inquired about weight, health issues or past usage.
Product Information and Pricing
Inside these groups, messages show black plastic packages with postal service stickers, stating to include new batches. One communication read: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at residence with sterile water, or ready-to-use injectors typically priced at 160 pounds for 20 milligrams. When asked how long a pen should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.
Service Oversight and Security Actions
A spokesperson for the messaging service stated it actively monitored dangerous material on its platform including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Cautions
“Individuals are administering substances they can’t verify. Although the science behind this drug is valid, these online versions may not include what they claim,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in demand to current price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are using online platforms. But counterfeit injections are highly risky. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.
Her team has previously seen individuals injured by self-injection from unverified sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is taking chances with your well-being,” stated Wyllie. “These materials could be impure or incorrectly dosed.”
Manufacturer Position
A representative from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this time no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company experimental product not yet approved … may subject users to potentially serious health risks”.
